Author | Tanya B. Dorff, MD


Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases

June 15, 2015

Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.

Salvage Chemotherapy for Refractory Germ Cell Tumors

June 15, 2014

When relapse occurs in patients with germ cell tumors, two salvage treatment paradigms exist: standard-dose chemotherapy, or high-dose chemotherapy with autologous stem cell rescue.

Weighing the Evidence for Immune Therapy and Targeted Therapy in Renal Cancer and Melanoma

July 15, 2013

Ultimately, as agents in both VEGF-targeted and immunotherapy classes with lower toxicity rates are developed, questions of combination and sequence will inspire clinical investigations of strategies that, it is hoped, will maximize both the quantity and quality of life for patients with RCC. Melanoma therapy drug development continues to lead the way with regard to what is therapeutically possible with immunotherapy-and suggests that HD IL-2 continues to be relevant in today’s treatment landscape.

Advanced Prostate Cancer: New Agents, New Questions

May 16, 2011

Drs. Ruch and Hussain provide an excellent overview of the emerging therapeutic agents and targets for advanced prostate cancer.